An interventional study of Sampling on blood, bone marrow and cerebrospinal fluid in Neuroblastoma, Rhabdomyosarcoma and Ewing Sarcoma Family of Tumors, sponsored by Institut Curie. Active, not recruiting at 30 sites in France. Open to participants aged 1 Year to 25 Years. Per ClinicalTrials.gov, last updated 2025-03-18.
Sponsored by Institut Curie · Not applicable, Interventional, and Other
Methodology:
Prospective, multicentric, open, non-randomised, non-therapeutic, interventional study
To identify and characterise:
675 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.
This study's planned enrollment of 600 is above the median of 32 across 507 interventional studies indexed under Neuroblastoma.
Browse Neuroblastoma studies →Institut Curie is the lead sponsor of 135 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Compulsory affiliation to a social security scheme
Additional inclusion criteria for the study:
To avoid multiple sampling for children, adolescents and young adults with cancer, patients already included or to be included in a study with similar analyses and/or objectives might also be included in MICCHADO study and in this case, samples or data might be exchanged on a collaborative basis.
Cohort 1:
High risk neuroblastoma:
High risk rhabdomyosarcoma:
High risk Ewing sarcoma:
High risk osteosarcoma:
High risk leukaemia:
Cohort 2:
Cohort 3:
Children, adolescents and young adults, with low/intermediate risk cancers belonging to the following types:
Stage 4s, in infants (younger than one year at diagnosis), without MYCN amplification
Localised, without Foxo1 rearrangement
Exclusion Criteria:
Main non-inclusion Criteria common to all study cohorts:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid
Other: Sampling on blood, bone marrow and cerebrospinal fluid
Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid
Other: Sampling on blood, bone marrow and cerebrospinal fluid
biological sampling during treatment and follow-up
Number of patients with meaningful molecular genetic alterations
Identification of molecular genetic alterations based on molecular characterisation of tumor at diagnosis, during patient treatment and follow-up (time dimension)
Time frame: At the end of study (6 years)
Number of patients with meaningful immunological features
Identification and characterisation of the tumor microenvironment and the host's immunological profile, at diagnosis and during patient treatment
Time frame: At the end of study (6 years)
Number of patients with identification of new tumor-specific genetic characteristics during follow-up (clonal evolution)
Comparison between genetic variations identified at diagnosis and those identified on circulating tumor DNA during treatment, FU and/or relapse
Time frame: up to 6 years
Correlation between disease recurrence and molecular and/or immunological biomarkers
To characterise biomarkers, based on molecular analyses of tumour samples from diagnosis, for prognostic and predictive purposes. To characterise the tumour microenvironment and the host's immunological profile, for prognostic and predictive purposes. To identify potential prognostic and predictive biomarkers on samples collected during patient's treatment and follow-up, based on changes on circulating tumour DNA (ctDNA), detected by molecular biology techniques, and on immunological findings
Time frame: up to 6 years
Correlation between genetic variations and immune parameters
To compare molecular and immunological findings at diagnosis and during treatment (data integration)
Time frame: up to 6 years
Correlation between disease staging and immunological features
To investigate the impact of the tumour microenvironment and host's immunological profile on the disease staging at diagnosis, by comparing patients with metastatic to patients with localised disease
Time frame: up to 6 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2018 (actual). Primary completion is estimated for Apr 2027, 107 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.